Journey Medical Corporation (DERM)
NASDAQ: DERM · Real-Time Price · USD
5.26
+0.06 (1.15%)
At close: Apr 14, 2026, 4:00 PM EDT
5.36
+0.10 (1.90%)
After-hours: Apr 14, 2026, 4:14 PM EDT
Journey Medical Stock Forecast
Stock Price Forecast
The 3 analysts that cover Journey Medical stock have a consensus rating of "Strong Buy" and an average price target of $12.67, which forecasts a 140.87% increase in the stock price over the next year. The lowest target is $12 and the highest is $13.
Price Target: $12.67 (+140.87%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Journey Medical stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 3 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $13 | Strong Buy | Reiterates | $13 | +147.15% | Mar 26, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $13 | Strong Buy | Initiates | $13 | +147.15% | Aug 25, 2025 |
| Lake Street | Lake Street | Strong Buy Maintains $9 → $13 | Strong Buy | Maintains | $9 → $13 | +147.15% | Aug 13, 2025 |
| B. Riley Securities | B. Riley Securities | Strong Buy Maintains $9 → $12 | Strong Buy | Maintains | $9 → $12 | +128.14% | Jul 30, 2025 |
| Lake Street | Lake Street | Strong Buy Initiates $9 | Strong Buy | Initiates | $9 | +71.10% | Sep 6, 2024 |
Financial Forecast
Revenue This Year
91.19M
from 61.86M
Increased by 47.42%
Revenue Next Year
142.20M
from 91.19M
Increased by 55.93%
EPS This Year
0.07
from -0.47
EPS Next Year
1.04
from 0.07
Increased by 1,303.45%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 104.6M | 167.2M | |
| Avg | 91.2M | 142.2M | |
| Low | 78.5M | 119.6M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 69.1% | 83.3% | |
| Avg | 47.4% | 55.9% | |
| Low | 26.9% | 31.2% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 0.23 | 1.69 | |
| Avg | 0.07 | 1.04 | |
| Low | -0.10 | 0.44 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | 2,186.0% | |
| Avg | - | 1,303.4% | |
| Low | - | 496.3% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.